Современное представление об иммунопатогенезе хронического гепатита В


DOI: https://dx.doi.org/10.18565/epidem.2020.4.73-79

Омарова Х.Г., Макашова В.В., Понежева Ж.Б., Хохлова О.Н.

ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора, Москва, Россия
Хроническая HBV-инфекция является динамическим процессом, отражающим взаимодействие между репликацией HBV и иммунным ответом хозяина. Согласно данным литературы, при хроническом гепатите B именно количественный состав и функции врожденных иммунных клеток оказывают выраженное влияние на вирус. Глубокое понимание иммунопатогенетических механизмов, вызванных отдельными антигенными компонентами HBV, которые вызывают как хронический гепатит B, так и его неблагоприятные исходы, послужит основой для применения прогностически значимых методов иммунодиагностики, а также эффективного лечения и профилактики заболевания.
Ключевые слова: гепатит В, иммунопатогонез, Т-лимфоциты, дендритные клетки

Литература


1. World Health Organization. Global hepatitis report, April 2017; 83. https://www.who.int/hepatitis/publications/global-hepatitis-report 2017/en/


2. World Health Organization. Hepatitis B Fact Sheet. http://www.who. int/mediacentre/factsheets/fs204/en/


3. EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017; 67: 370–98. https://doi.org/10.1016/ j.jhep.2017.03.021


4. Жданов К.В., Лобзин Ю.В., Гусев Д.А., Козлов К.В. Вирусные гепатиты. СПб: Фолиант, 2011. 304 с.

Zhdanov K.V., Lobzin Yu.V., Gusev D.A., Kozlov K.V.


5. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167–85.


6. Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546–55.


7. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 288 с.

Abdurakhmanov D.T.


8. Baumert T.F., Thimme R., von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 2007; 13: 82–90. https://doi.org/ 10.3748/wjg.v13.i1.82


9. Balmasova I.P., Yushchuk N.D., Mynbayev O.A., Alla N.R., Malova E.S., Shi Z., Gao K.I.


10. Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol. Commun. 2018; 3(1): 8–19. doi:10.1002/hep4.1281


11. Seeger C., Mason W.S. Molecular biology of hepatitis B virus infection J. Virol. 2015; 479–480: 672–86. https://doi.org/10.1016/j.virol.2015.02.031


12. Lee J., Shin M.K., Lee H.J., Yoon G., Ryu W.S. Three novel cis-acting elements required for efficient plus-strand DNA synthesis of the hepatitis B virus genome. J. Virol. 2004; 78: 7455–64. doi: 10.1128/JVI.78.14.7455-7464.2004


13. Bertoletti A., Kennedy P.T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol. Immunol. 2015; 12(3): 258–63. doi: 10.1038/cmi.2014.79


14. Said Z.N. An overview of occult hepatitis B virus infection. World. J. Gastroenterol. 2011; 17(15): 1927–38. doi: 10.3748/wjg.v17.i15.1927.


15. Wong D.K., Huang F.Y., Lai C.L., Poon R.T, Seto W.K., Fung J. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829–36. doi: 10.1002/hep.24551


16. Roseman A.M., Borschukova O., Berriman J.A., Wynne S.A., Pumpens P., Crowther R.A. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J. Mol. Biol. 2012; 423(1): 63–78. doi: 10.1016/j.jmb.2012.06.032.


17. Block T.M., Mehta A.S., Blumberg B.S., Dwek R.A. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity? DNA Cell Biol. 2006; 25 (3):165–70. doi: 10,1089/dna.2006.25.165


18. Li L., Liu M., Cheng L.W., Gao X.Y., Fu J.J., Kong G. et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand. J. Immunol. 2013; 78(5): 439–46. doi: 10.1111/sji.12099


19. Buchmann P., Dembek C., Kuklick L., Jäger C., Tedjokusumo R., von Freyend M.J. et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31(8):1197–203. doi: 10.1016/ j.vaccine.2012.12.074


20. You J., Sriplung H., Geater A., Chongsuvivatwong V., Zhuang L., Chen H.Y. et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol. 2008; 14(7): 1112–9. doi: 10.3748/wjg.14.1112


21. Block T.M., Guo H., Guo J.T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 2007; 11(4): 685–706. doi: 10.1016/j.cld.2007.08.002


22. Shi Y.H., Shi C.H. Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol. 2009; 15(25): 3099–105. doi: 10.3748/wjg.15.3099


23. Li N., Li Q., Qian Z., Zhang Y., Chen M., Shi G. Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem. Biophys. Res. Commun. 2009; 390(3):.630–5. doi: 10.1016/j.bbrc.2009.10.018


24. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214(2): 199–210. doi: 10,1002/path.2277


25. Shi F., Zhang J.Y, Zeng Z., Tien P., Wang F.S. Skewed ratios between CD3(+) T cells and monocytes are associated with poor prognosis in patients with HBV-related acute-on-chronic liver failure. Biochem. Biophys. Res. Commun. 2010; 402(1): 30–6. doi: 10.1016/j.bbrc.2010.09.096


26. Feitelson M.A., Reis H.M.G.P.V., Liu J., Lian Z., Pan J. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenezis. Frontiers in Bioscience 2005; 10: 1558–72. doi: 10,2741/1640


27. Zhang Z., Zhang J.Y., Wang L.F., Wang F.S. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2012; 27(2): 223–30. doi: 10.1111/j.1440-1746. 2011.06940.x


28. Kim J.Y., Song E.H., Lee H.J., Oh Y.K., Choi K.H., Yu D.Y. et al. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J. Mol. Biol. 2010; 397(4): 917–31. doi: 10.1016/j.jmb.2010.02.016


29. Dunn C., Brunetto M., Reynolds G., Christophides T., Kennedy P.T., Lampertico P. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 2007; 204(3): 667–80. doi: 10.1084/jem.20061287


30. Ratnam D., Visvanathan K. New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatol. Int. 2008; 2(Suppl.1): 12–8. doi: 10.1007/s12072-008-9067-0


31. Chen J., Wu M., Zhang X., Zhang W., Zhang Z., Chen L. et al. Hepatitis B virus polymerase impairs interferon-α-induced STAT activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 2013; 57(2): 470–82. doi: 10.1002/hep.26064


32. Ito T., Kanzler H., Duramad O., Cao W., Liu Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006; 107(6): 2423–31. DOI: 10,1182/кровь-2005-07-2709


33. Ma Y.J., He M., Han J.A., Yang L., Ji X.Y. A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand. J. Immunol. 2013; 78(4): 387–93. doi: 10.1111/sji.12097


34. Хохлова О.Н., Серебровская Л.В., Ходжибеков Р.Р., Гезахегне Д.Б., Кожевникова Г.М., Покровский В.В., Рейзис А.Р. Роль плазмоцитоидных дендритных клеток как новых иммуноцитов в патогенезе ХГС, ХГВ И ВИЧ-инфекции. Инфекционные болезни 2016; 14(4): 31–6.

Khokhlova O.N., Serebrovskaya L.V., Khodzhibekov R.R., Gezakhegne D.B., Kozhevnikova G.M., Pokrovskiy V.V., Reizis A.R.


35. Woltman A.M., Ter Borg M.J., Binda R.S., Sprengers D., von Blomberg B.M., Scheper R.J. et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir. Ther. 2009; 14(6): 809–18. doi: 10,3851/IMP1295


36. Sun H.H., Zhou D.F., Zhou J.Y. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J. Med. Virol. 2016; 88: 13–20. doi:10.1002/jmv.24306


37. Duan X.Z., Wang M., Li H.W., Zhuang H., Xu D., Wang F.S. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol. 2004; 24(6): 637–46. DOI: 10.1007/s10875-004-6249-y


38. Opden Brouw M.L., Binda R.S., van Roosmalen M.H., Protzer U., Janssen H.L., van der Molen R.G., Woltman A.M. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126(2): 280–9. doi: 10.1111/j.1365-2567.2008.02896.x


39. Сепиашвили Р.И., Балмасова И.П., Кабанова Е.В., Малова Е.С., Славянская Т.А. Вирус гепатита В: биология, иммунопатогенез, система NK/NKT в вирусной персистенции. Журн. микробиол., эпидемиол., иммунол. 2006; (6): 76–83. PMID: 17163145

Sepiashvili R.I., Balmasova I.P., Kabanova E.V., Malova E.S., Slavianskaya TA.


40. Lang K.S., Georgiev P., Recher M., Navarini A.A., Bergthaler A., Heikenwalder M. et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006; 116(9): 2456–63. DOI: 10,1172/JCI28349


41. Moretta A., Marcenaro E., Parolini S., Ferlazzo G., Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death. Differ. 2008; 15(2): 226–33. DOI: 10,1038/sj.cdd.4402170


42. Stoop J.N., Woltman A.M., Biesta P.J., Kusters J.G., Kuipers E.J., Janssen H.L., van der Molen R.G. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 2007; 46(3): 699–705. DOI: 10.1002/hep.21761


43. Jinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N. et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4+CD25+ T cells with PD-1-dependent regulatory activities. Immunology 2007; 120(1): 73–82. DOI: 10,1111/j.1365-2567.2006.02479.x


44. Weng P.J., Ying H., Hong L.Z., Zhou W.H., Hu Y.R., Xu C.H. An analysis of CD3+CD56+ lymphocytes and their subsets in the peripheral blood of patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2008; 16(9): 654–6.


45. Rauch A., Laird R., McKinnon E., Telenti A., Furrer H., Weber R. et al. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens 2007; 69 (Suppl 1): 237–40. DOI: 10,1111/j.1399-0039.2006.773_4.x


46. Peng G., Li S., Wu W., Sun Z., Chen Y., Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008; 123(1): 57–65. DOI: 10.1111/j.1365-2567.2007.02691.x


47. Zhang L., Zhao Y.. The regulation of Foxp3 expression in regulatory CD4(+) CD25(+) T cells: multiple pathways on the road. J. Cell Physiol. 2007; 211(3): 590–97. DOI: 10.1002/ jcp.21001


48. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D. et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445(7130): 931–5. DOI: 10.1038/nature05478


49. Manigold T., Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis. 2007; 7(12): 804–13. DOI: 10.1016 / S1473-3099 (07)70289-X


50. Guo J.C., Bao J.F., Chen Q.W., Li X.O., Shi J.P., Lou G.Q. et al. Level of serum and liver tissue TGF-beta1 in patients with liver fibrosis due to chronic hepatitis B. Zhonghua Shiyan He Linchuangbingduxue Zazhi 2008; 22(5): 354–7.


51. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006; 176(11): 6752–61. DOI: 10.4049/ jimmunol.176.11.6752


52. Aalaei-Andabili S.H., Alavian S.M. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine 2012; 30(38): 5595–602. doi: 10.1016/j.vaccine.2012.06.063


53. Feng I.C., Koay L.B., Sheu M.J., Kuo H.T., Sun C.S., Lee C. et al. HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J. Biomed. Sci. 14(this issue), doi 10.1007/s11373-006-9129-z


54. Shimizu Y. T-cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World. J. Gastroenterol. 2012; 18(20): 2443–51. Doi: 10.3748/wjg.v18.i20.2443


55. Chen J., Wang X.M., Wu X.J., Wang Y., Zhao H., Shen B., Wang G.Q. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm. Res. 2011; 60(1): 47–53. doi: 10.1007/ s00011-010-0233-1


56. Nan X.P., Zhang Y., Yu H.T., Li Y., Sun R.L., Wang J.P., Bai X.F. Circulating CD4+CD25 high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol. 2010; 23(1): 63–70. doi: 10.1089/vim.2009.0061


57. Zhang G.L., Xie D.Y., Lin B.L., Xie C., Ye Y.N., Peng L. et al. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 2013; 28(3): 513–21. doi: 10.1111/jgh.12082


58. Kitani A., Xu L. Regulatory T cells and the induction of IL-17. Mucosal Immunol. 2008; 1(Suppl 1): S43–S46. doi: 10.1038/mi.2008.51


59. Zhang G.L., Xie D.Y., Ye Y.N., Lin C.S., Zhang X.H., Zheng Y.B. et al. High level of IL-27 positively correlated with Th17 cells may indicate liver injury in patients infected with HBV. Liver Int. 2014; 34(2): 266–73. doi: 10.1111 /liv.12268


60. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di Vincenzo P. et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134(5): 1470–81. doi: 10.1053/j.gastro.2008.02.017


Об авторах / Для корреспонденции


Омарова Хадижат Гаджиевна – к.м.н, научный сотрудник клинического отдела инфекционной патологии ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора; Москва, Россия; е-mail: omarova71@inbox.ru; ORCID: http://orcid.org/0000-0002-9682-2230
Макашова Вера Васильевна – д.м.н., профессор, ведущий научный сотрудник ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора, Москва, Россия; е-mail: veramakashova@yandex.ru ORCID: https://orcid.org/0000-0002-0982-3527
Понежева Жанна Бетовна – д.м.н., заведующая клиническим отделом инфекционной патологии ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора, Москва, Россия; е-mail: doktorim@mail.ru; ORCID: https://orcid.org/0000-0002-6539-4878
Хохлова Ольга Николаевна – к.м.н, научный сотрудник клинического отдела инфекционной патологии ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора Москва, Россия; е-mail: x.olia79@mail.ru ORCID: https://orcid.org/0000-0001-9736-4043


Бионика Медиа